Actively Recruiting
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Led by GlaxoSmithKline · Updated on 2025-10-14
392
Participants Needed
56
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable GSK5733584 is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.
CONDITIONS
Official Title
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years of age or older at the time of consent.
- Participant must be able to give signed informed consent and comply with study requirements.
- Participants must have pathologically confirmed advanced solid tumor relevant to study arms with no more than 4 prior systemic therapies.
- Archival or fresh tumor tissue must be provided for biomarker analysis.
- Participants must have at least one measurable target lesion per RECIST 1.1.
- Participants must have a life expectancy of at least 12 weeks.
- For endometrial cancer Part A: advanced or recurrent disease, failed or intolerant to standard treatments, and not candidates for curative radiotherapy.
- For endometrial cancer Part B: mismatch repair proficient or microsatellite stable tumor, progressed or intolerant to at least one prior therapy, and naive to PD-1/PD-L1 therapy.
- For ovarian cancer Part A: confirmed advanced epithelial ovarian/fallopian tube/peritoneal cancer, failed or intolerant to standard treatments.
- For ovarian cancer Part B: platinum-sensitive relapse, progressed or intolerant to at least one prior chemotherapy, and not candidates for second cytoreductive surgery.
- Participants willing to use adequate contraception.
- Male participants must agree to refrain from sperm donation during and for at least 6 to 11 months after treatment depending on study arm.
- Female participants must not be pregnant or breastfeeding and must use effective contraception if of childbearing potential.
- Participants must have ECOG performance status 0 to 1.
- Participants must have normal organ and bone marrow function.
You will not qualify if you...
- Participants with a second malignancy requiring treatment or progressed within 24 months except certain skin and in-situ carcinomas.
- History of bone marrow or solid organ transplant.
- Known sensitivity or allergy to study drugs or components.
- Significant or uncontrolled cardiac disease or arrhythmia.
- Current or prior interstitial lung disease or pneumonitis.
- Autoimmune disease requiring systemic treatment in past 2 years.
- Significant bleeding or bleeding tumors within 1 month prior to treatment.
- Poorly controlled hypertension or recent hypertensive crisis.
- Active renal conditions affecting safety.
- Known HIV infection.
- Elevated liver enzymes above specified limits.
- Elevated total bilirubin above 1.5 times upper normal limit.
- Recent treatment with chemotherapy or anti-tumor drugs within 30 days or 5 half-lives.
- Use of strong/moderate CYP3A4, CYP2D6 inhibitors or inducers or P-gp/BCRP inhibitors or inducers within 14 days prior.
- Recent locoregional radiation therapy within 2 weeks or extensive bone marrow irradiation within 4 weeks prior to treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 56 locations
1
GSK Investigational Site
Buenos Aires, Argentina, C1280AEB
Actively Recruiting
2
GSK Investigational Site
CABA, Argentina, C1187
Actively Recruiting
3
GSK Investigational Site
Viedma, Argentina, R8500ACE
Actively Recruiting
4
GSK Investigational Site
Liverpool, New South Wales, Australia, 2170
Actively Recruiting
5
GSK Investigational Site
Wollongong, New South Wales, Australia, 2500
Actively Recruiting
6
GSK Investigational Site
Brussels, Belgium, 1200
Actively Recruiting
7
GSK Investigational Site
Ghent, Belgium, 9000
Actively Recruiting
8
GSK Investigational Site
Leuven, Belgium, 3000
Actively Recruiting
9
GSK Investigational Site
Liège, Belgium, 4000
Actively Recruiting
10
GSK Investigational Site
Natal, Brazil, 59075-740
Actively Recruiting
11
GSK Investigational Site
Porto Alegre, Brazil, 90020-090
Actively Recruiting
12
GSK Investigational Site
São Paulo, Brazil, 01246-000
Actively Recruiting
13
GSK Investigational Site
Vitória, Brazil, 29043-260
Actively Recruiting
14
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
15
GSK Investigational Site
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
16
GSK Investigational Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
17
GSK Investigational Site
Copenhagen, Denmark, 2100
Actively Recruiting
18
GSK Investigational Site
Helsinki, Finland, 00029
Actively Recruiting
19
GSK Investigational Site
Tampere, Finland, 33520
Actively Recruiting
20
GSK Investigational Site
Montpellier, France, 34298
Actively Recruiting
21
GSK Investigational Site
Pierre-Bénite, France, 69495
Actively Recruiting
22
GSK Investigational Site
Villejuif, France, 94805
Actively Recruiting
23
GSK Investigational Site
München, Germany, 81377
Actively Recruiting
24
GSK Investigational Site
Athens, Greece, 11528
Actively Recruiting
25
GSK Investigational Site
Athens, Greece, 12462
Actively Recruiting
26
GSK Investigational Site
Pylaia Thessaloniki, Greece, 570 01
Actively Recruiting
27
GSK Investigational Site
Thessaloniki, Greece, 55236
Actively Recruiting
28
GSK Investigational Site
Chiba, Japan, 277-8577
Actively Recruiting
29
GSK Investigational Site
Fukuoka, Japan, 811-1395
Actively Recruiting
30
GSK Investigational Site
Tokyo, Japan, 104-0045
Actively Recruiting
31
GSK Investigational Site
Tokyo, Japan, 135-8550
Actively Recruiting
32
GSK Investigational Site
Amsterdam, Netherlands, 1066 CX
Actively Recruiting
33
GSK Investigational Site
Rotterdam, Netherlands, 3015 GD
Actively Recruiting
34
GSK Investigational Site
Oslo, Norway, 0379
Actively Recruiting
35
GSK Investigational Site
Panama City, Panama
Actively Recruiting
36
GSK Investigational Site
Panama City, Panama
Actively Recruiting
37
GSK Investigational Site
Punta Pacifica Panama City Panama, Panama
Actively Recruiting
38
GSK Investigational Site
Józefów, Poland, 05-410
Actively Recruiting
39
GSK Investigational Site
Warsaw, Poland, 01-748
Actively Recruiting
40
GSK Investigational Site
Seoul, South Korea, 05505
Actively Recruiting
41
GSK Investigational Site
Seoul, South Korea, 120-752
Actively Recruiting
42
GSK Investigational Site
Barcelona, Spain, 08023
Actively Recruiting
43
GSK Investigational Site
Barcelona, Spain, 08035
Actively Recruiting
44
GSK Investigational Site
Barcelona, Spain, 08036
Actively Recruiting
45
GSK Investigational Site
Madrid, Spain, 28033
Actively Recruiting
46
GSK Investigational Site
Madrid, Spain, 28041
Actively Recruiting
47
GSK Investigational Site
Madrid, Spain, 28050
Actively Recruiting
48
GSK Investigational Site
Málaga, Spain, 29010
Actively Recruiting
49
GSK Investigational Site
Valencia, Spain, 46009
Actively Recruiting
50
GSK Investigational Site
Zaragoza, Spain, 50009
Actively Recruiting
51
GSK Investigational Site
Stockholm, Sweden, 17164
Actively Recruiting
52
GSK Investigational Site
Ankara, Turkey (Türkiye), 06590
Actively Recruiting
53
GSK Investigational Site
Ankara, Turkey (Türkiye), 6170
Actively Recruiting
54
GSK Investigational Site
Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
55
GSK Investigational Site
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
56
GSK Investigational Site
London, United Kingdom, NW1 2BU
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here